USPTO 2015–2025 USPTO PatentsView US Corporation

Abbott Molecular Inc.

USPTO PatentsView assignee record — 95 granted patents across 19 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

95
Total patents granted
19
CPC technology areas
13.7
Avg claims per patent
-36%
5-year filing velocity

The verdict

Abbott holds 95 US patents across 19 technology areas — rank #3,797 of 50,000 tracked assignees.

#3,797
of 50,000 US assignees by volume
Top 33%
by Innovation Score (41.4/100)
13.7
avg claims per patent
-36%
filing velocity, last 5 yrs

Portfolio overview

Abbott Molecular Inc. has been granted 95 US utility patents between 2015 and 2025, placing Abbott Molecular Inc. at rank #3,797 across all assignees tracked by PlainPatent. This portfolio spans 19 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.7 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Abbott Molecular Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 41.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 37 grants, compared with 58 in the 2015–2019 window — a -36% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Abbott Molecular Inc.'s 13.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 19 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Abbott Molecular Inc. against peers pursuing similar technology classes.

How does Abbott compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Abbott holds 95 patents — placing it at rank #3,797 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Abbott's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

41 Top 33% higher than 67% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

05101520 20152016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Abbott Molecular Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 9 9.5%
2016 11 11.6%
2017 9 9.5%
2018 18 18.9%
2019 11 11.6%
2020 14 14.7%
2021 11 11.6%
2022 6 6.3%
2023 1 1.1%
2024 4 4.2%
2025 1 1.1%

Which technologies does Abbott Molecular Inc. patent most?

Top 15 of 19 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#3,797

Across all tracked assignees

Innovation Score

41.4 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Abbott Molecular Inc. hold?
Abbott Molecular Inc. holds 95 US granted patents filed between 2015 and 2025, spanning 19 technology areas.
What is Abbott Molecular Inc.'s Innovation Score?
Abbott Molecular Inc. has an Innovation Score of 41.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Abbott Molecular Inc. focus on?
Abbott Molecular Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 80 patents. The company has filed patents in 19 CPC subclasses total.
Is Abbott Molecular Inc.'s patent filing rate increasing or decreasing?
Abbott Molecular Inc.'s recent filing velocity is -36% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Abbott Molecular Inc.'s patents?
Abbott Molecular Inc.'s patents average 13.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Abbott Molecular Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Abbott's 95 grants land it in the top 33% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Abbott ranks #3,797 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q — see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov